Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR Prostate-05
2026-526275-38-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Saruparib + physician's choice ARPI with Placebo + physician's choice ARPI (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2026-526275-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526275-38-00.